keyword
MENU ▼
Read by QxMD icon Read
search

azathioprine crohn

keyword
https://www.readbyqxmd.com/read/29104132/clinical-and-pharmacokinetic-factors-associated-with-adalimumab-induced-mucosal-healing-in-patients-with-crohn-s-disease
#1
Kenji Watanabe, Takayuki Matsumoto, Tadakazu Hisamatsu, Hiroshi Nakase, Satoshi Motoya, Naoki Yoshimura, Tetsuya Ishida, Shingo Kato, Tomoo Nakagawa, Motohiro Esaki, Masakazu Nagahori, Toshiyuki Matsui, Yuji Naito, Takanori Kanai, Yasuo Suzuki, Masanori Nojima, Mamoru Watanabe, Toshifumi Hibi
BACKGROUND & AIMS: We previously reported results from a prospective randomized controlled trial comparing the efficacy of adalimumab monotherapy vs combination with azathioprine for patients with Crohn's disease (CD) who were naïve to biologics and thiopurines. We performed a sub-analysis of data from this study to evaluate factors associated with endoscopic response and mucosal healing in study participants. METHODS: We compared simple endoscopic scores for CD (SES-CD) in between patients with moderate to severe active CD randomly assigned groups that received adalimumab monotherapy (n=85) or adalimumab in combination with azathioprine (n=91), from June 2011 to June 2014 in Japan...
November 2, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29096949/effect-of-tight-control-management-on-crohn-s-disease-calm-a-multicentre-randomised-controlled-phase-3-trial
#2
Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Milan Lukas, Filip Baert, Tomas Vaňásek, Ahmet Danalioglu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hébuterne, Simon Travis, Silvio Danese, Walter Reinisch, William J Sandborn, Paul Rutgeerts, Daniel Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Paloma Mendez, Joel Petersson, Kori Wallace, Anne M Robinson, Roopal B Thakkar, Geert D'Haens
BACKGROUND: Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn's disease, but whether their use in treatment decisions improves outcomes is unknown. We aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients managed with a clinical management algorithm...
October 30, 2017: Lancet
https://www.readbyqxmd.com/read/29069227/bone-mineral-density-and-inflammatory-bowel-disease-severity
#3
C A Lima, A C Lyra, C M C Mendes, M B Lopes, F G Coqueiro, R Rocha, G O Santana
Inflammatory bowel disease (IBD) is associated with low bone mineral density (BMD). In this study, the association between disease severity and BMD in patients with IBD was evaluated. Associations between BMD and the Montreal classification, disease activity and drug therapy were also tested. A cross-sectional prevalence study with a comparison group was conducted. One hundred and twenty-eight patients were evaluated: 68 patients with ulcerative colitis (UC), and 60 with Crohn's disease (CD). The control group consisted of 67 healthy subjects...
October 19, 2017: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
https://www.readbyqxmd.com/read/29051788/emerging-oral-targeted-therapies-in-inflammatory-bowel-diseases-opportunities-and-challenges
#4
REVIEW
Marcel Vetter, Markus F Neurath
To improve quality of life and prevent long-term risks in patients with inflammatory bowel diseases (IBDs: Crohn's disease, ulcerative colitis), it is essential to suppress inflammatory activity adequately. However, corticosteroids are only suitable for therapy of acute flares and the evidence for positive effects of immunosuppressive substances like azathioprine or 6-mercapropurine is mainly limited to maintenance of remission. In addition, only subgroups of patients benefit from biologicals targeting tumour necrosis factor α or α4β7 integrins...
October 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28986660/risk-factors-for-rescue-therapy-in-crohn-s-patients-maintained-on-infliximab-after-withdrawal-of-the-immunomodulator-a-long-term-follow-up
#5
Monika Fischer, Sarah C Campbell, Cynthia S J Calley, Debra J Helper, Michael V Chiorean, Hala M Fadda
BACKGROUND: Usefulness of thiopurine and scheduled infliximab combination therapy in non-immunomodulator (IM)-naïve Crohn's disease (CD) patients and the optimal length of dual therapy are still debated. AIMS: To determine proportion of patients developing disease flare requiring rescue therapy and risk factors associated with disease flare after de-escalation of IM from combination therapy. METHODS: Adult CD patients in clinical remission on combination therapy were identified from a large single-center database between 2002 and 2009...
November 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28967958/visceral-leishmaniasis-infection-in-a-patient-with-crohn-s-disease-treated-with-azathioprine
#6
Teresa Valdés Delgado, Patricia Cordero Ruiz, Francisco Bellido Muñoz
No abstract text is available yet for this article.
October 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28961694/a-severe-neonatal-lymphopenia-associated-with-administration-of-azathioprine-to-the-mother-in-a-context-of-crohn-s-disease
#7
C Thomas, C Monteil-Ganiere, S Mirallié, C Hémont, C Dert, A Léger, C Joyau, D Caldari, M Audrain
Azathioprine is commonly used in Crohn's Diseases. It has been administered to many pregnant women over many years without significant side effects. However, pancytopenia and Severe Combined Immune Deficiency-like disease have been reported in infants whose mothers received azathioprine throughout pregnancy. Moreover, myelotoxicity has been described in patients treated with azathioprine and having a low or absent thiopurine S-methyl transferase (TPMT) activity.Here, we describe the case of a new-born girl found highly lymphopenic (<300 CD3+ T cells) after a positive new-born screening for Severe Combined Immuno Deficiency...
September 2, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28948431/vulvar-involvement-in-pediatric-crohn-s-disease-a-systematic-review
#8
REVIEW
Roberta Granese, Gloria Calagna, Giuliana Morabito, Carmine Carriero, Antonio Perino, Gabriele Tonni, Claudio Romano
PURPOSE: The aim of the study is to report a systematic review (from 2000 to 2017) of all pediatric cases of vulvar Crohn's disease (VCD) and to highlight the key-points for a correct diagnosis and management of this rare condition. METHODS: An electronic search using the Pubmed/Medline, Scopus, EMBASE, Cochrane database and Google Scholar database was performed according to PRISMA guidelines. RESULTS: Twenty pediatric studies and 22 cases of VCD were included for analysis...
September 25, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28940780/prolonged-azathioprine-treatment-reduces-the-need-for-surgery-in-early-crohn-s-disease
#9
Yun Qiu, Bai-Li Chen, Rui Feng, Sheng-Hong Zhang, Yao He, Zhi-Rong Zeng, Shomron Ben-Horin, Laurent Peyrin-Biroulet, Ren Mao, Min-Hu Chen
BACKGROUND AND AIM: Whether an early use of azathioprine (AZA) can alter the natural history of Crohn's disease (CD) remains debated. To evaluate the impact of AZA on disease progression in a cohort of patients with early CD. METHODS: This longitudinal cohort study examined patients with early CD defined as disease duration ≤18 months and no previous use of disease-modifying agents according to Paris definition. The primary outcome was the proportion of CD-related intestinal surgery...
September 22, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28929775/hypersensitivity-to-azathioprine-in-a-patient-with-crohn-s-disease-a-case-report
#10
Mafalda Sousa, Luísa Proença, João Carvalho
Azathioprine (AZA) is commonly used in inflammatory bowel disease and many other medical diseases. The most common adverse events of AZA include gastrointestinal effects, hepatotoxicity, myelotoxicity and pancreatitis.
October 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28922253/long-term-efficacy-safety-and-immunogenicity-of-biosimilar-infliximab-after-one-year-in-a-prospective-nationwide-cohort
#11
Lorant Gonczi, Krisztina B Gecse, Zsuzsanna Vegh, Zsuzsanna Kurti, Mariann Rutka, Klaudia Farkas, Petra A Golovics, Barbara D Lovasz, Janos Banai, Laszlo Bene, Bea Gasztonyi, Tunde Kristof, Laszlo Lakatos, Pal Miheller, Ferenc Nagy, Karoly Palatka, Maria Papp, Arpad Patai, Agnes Salamon, Tamas Szamosi, Zoltan Szepes, Gabor T Toth, Aron Vincze, Balazs Szalay, Tamas Molnar, Peter L Lakatos
BACKGROUND: It has been previously shown that biosimilar infliximab CT-P13 is effective and safe in inducing remission in inflammatory bowel diseases. We report here the 1-year outcomes from a prospective nationwide inflammatory bowel disease cohort. METHODS: A prospective, nationwide, multicenter, observational cohort was designed to examine the efficacy and safety of CT-P13 in the induction and maintenance treatment of Crohn's disease (CD) and ulcerative colitis (UC)...
November 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28917218/erythema-elevatum-diutinum-in-crohn-s-disease-associated-spondyloarthritis-a-rare-vasculitis-an-unusual-association
#12
Maria João Gonçalves, Vasco C Romão, Luís Soares-de-Almeida, Helena Canhão, José Carlos Romeu, Heinz Kutzner, José Alberto Pereira-da-Silva
Erythema elevatum diutinum is a rare neutrophilic dermatoses with vasculitis, which presents as persistent, symmetrical, purple or brownish papules and nodules, mainly in the extensor surface of the limbs. We describe a case of erythema elevatum diutinum and polyarthritis as initial manifestations of Crohn's disease associated spondyloarthritis. A 51-year-old man, from São Tomé e Príncipe, with previous history of treated tuberculosis and chronic hepatitis B infection, was admitted due to 4 months history of polyarthritis, hyperpigmented papules on the extensor surfaces, occasional episodes of bloody mucous diarrhea and significant weight loss...
September 14, 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/28906316/secondary-loss-of-response-to-infliximab-in-pediatric-crohn-s-disease-does-it-matter-how-and-when-we-start
#13
Rishi Bolia, Jeremy Rosenbaum, Vered Schildkraut, Winita Hardikar, Mark Oliver, Donald Cameron, George Alex
OBJECTIVES: A significant proportion of children with Crohn's disease develop a secondary loss of response (LOR) to infliximab. Our aim was to study the impact of initial treatment strategies on secondary LOR. METHODS: We reviewed the medical records of children with Crohn's disease who received scheduled maintenance infliximab therapy for at least 12 months. We compared children who developed LOR with those who did not; with regards to their clinical and laboratory parameters, disease phenotype and treatment strategy before developing LOR...
September 12, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28826742/a-comprehensive-review-and-update-on-crohn-s-disease
#14
Mahesh Gajendran, Priyadarshini Loganathan, Anthony P Catinella, Jana G Hashash
The term inflammatory bowel disease (IBD) refers principally to two major categories of chronic relapsing inflammatory intestinal disorders: Crohn's disease (CD) and ulcerative colitis (UC). In the United States, it is currently estimated that about 1.5 million people suffer from IBD, causing considerable suffering, mortality and economic loss every year. Yet the cause of IBD is unknown, and until we understand more, prevention or cure will not be possible. There is a lot of variation in the incidence and prevalence of CD based on geographic region, environment, immigrant population, and ethnic groups...
August 18, 2017: Disease-a-month: DM
https://www.readbyqxmd.com/read/28752504/die-oralen-auswirkungen-von-morbus-crohn-beschreibung-von-neun-f%C3%A3-llen
#15
Tuncay Sahin, Alexandre Brygo, Emmanuel Delaporte, Joël Ferri
Crohn’s disease (CD) is a chronic inflammatory bowel disease whose oral features remain underrated at clinical examination. The aim of the study was to report forerunner orofacial presentations leading to diagnosis of CD among nine patients of mean age 23 between 2008 and 2015. Linear ulcerative buccal lesions, cobblestoning, mucosal tags and perioral erythema are highly evocative and might precede intestinal signs for several years. Oral biopsies revealed highly suggestive lesions of CD for 45% of patients before any intestinal symptom or digestive investigation...
2017: Swiss Dental Journal
https://www.readbyqxmd.com/read/28699600/extracellular-matrix-protein-1-gene-rs3737240-single-nucleotide-polymorphism-is-associated-with-ulcerative-colitis-in-turkish-patients
#16
Gupse Adalı, Nagehan Ersoy Tunalı, Elif Yorulmaz, Necip Ozan Tiryakioğlu, Sibel Güray Mungan, Celal Ulaşoğlu, Feruze Yılmaz Enç, İlyas Tuncer
BACKGROUND/AIMS: Ulcerative colitis (UC) and Crohn's disease are chronic inflammatory diseases. Genetic, immunologic, and microbial factors play an important role in their pathogenesis. Extracellular matrix protein 1 (ECM1), a gene related to mucosal barrier function, has been shown to be associated with UC. This study aims to determine the relationship between ECM1 gene rs3737240 single nucleotide polymorphism (SNP) and UC in a group of Turkish patients. MATERIALS AND METHODS: Ninety-four UC patients and 120 healthy controls were enrolled in the study...
July 2017: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/28679512/guillain-barr%C3%A3-syndrome-in-association-with-antitumour-necrosis-factor-therapy-a-case-of-mistaken-identity
#17
Kurvi Patwala, Nicholas Crump, Peter De Cruz
Guillain-Barré syndrome (GBS) is an immune-mediated disease characterised by evolving ascending limb weakness, sensory loss and areflexia. Two-thirds of GBS cases are associated with preceding infection. However, GBS has also been described in association with antitumour necrosis factor (TNF) therapies including infliximab and adalimumab for chronic inflammatory disorders such as rheumatoid arthritis, ankylosing spondylitis and inflammatory bowel disease. We present the case of a patient who developed GBS while undergoing treatment with adalimumab in combination with azathioprine for severe fistulising Crohn's disease, and review the literature on neurological adverse events that occur in association with anti-TNF therapy...
July 5, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28651460/-gut-liver-axis-in-inflammatory-bowel-disease-a-retrospective-study
#18
Anna Egresi, Ágota Kovács, Ágnes Szilvás, Anna Blázovics
INTRODUCTION: Examination of the gut-liver axis came into the spotlight worldwide. Liver enzyme elevations are commonly seen in patients with inflammatory bowel disease (IBD), which is a diagnostic challenge in everyday clinical practice. Liver and biliary diseases are common extra-intestinal manifestations in Crohn's disease and ulcerative colitis. The assessment of routine liver function tests could be an inaccurate reflection of liver damage, so its prevalence could be underestimated...
July 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28631133/bone-density-in-pediatric-crohn-s-disease-a-cross-sectional-observation-from-south-india
#19
Shiraz Salim Khan, Sagar S Patil
BACKGROUND: Crohn's disease (CD) frequently manifests in the second and third decades of life. Malnutrition and corticosteroid therapy may affect bone mineralization and delay bone growth. Our aim was to study bone mineral density and factors associated low bone mineral density (BMD) in pediatric CD. METHODS: A cross-sectional observational study in children with CD (aged 5 to <18 years) was done. Demographic and treatment details were noted. Vitamin D levels <20 ng/mL were considered as deficiency...
May 2017: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
https://www.readbyqxmd.com/read/28630623/strategies-for-preventing-endoscopic-recurrence-of-crohn-s-disease-1-year-after-surgery-a-network-meta-analysis
#20
REVIEW
Jin-Shan Feng, Jin-Yu Li, Xiu-Yan Chen, Zheng Yang, Shang-Hai Li
OBJECTIVE: To assess the benefits of different treatments that aim to prevent the endoscopic recurrence of Crohn's disease (CD) after ileal resection. METHODS: Randomized controlled trials (RCTs) were searched from MEDLINE, Embase, and the Cochrane Central Database. All the included RCTs with an endoscopic recurrence outcome which was defined as Rutgeerts' score ≥ i2 have a duration of more than 1 year. The quality of the included RCTs was assessed by the Cochrane Risk of Bias Tool...
2017: Gastroenterology Research and Practice
keyword
keyword
30477
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"